Top-News

Intensity Therapeutics Inc Aktie

Aktie
WKN:  ISIN:  US45828J1034 US-Symbol:  INTS
2,0295 €
-0,1429 €
-6,58%
2,13 $ 18:39:01 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
13,71 Mio.
Marktkapitalisierung *
35,23 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
*Stand: 15.12.2023

Intensity Therapeutics Inc News

08:00 Uhr - PR Newswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, ...
21.11.24 - PR Newswire
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
18.11.24 - PR Newswire
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-...
13.11.24 - PR Newswire
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
08.11.24 - PR Newswire
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-​Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting PR Newswire
31.10.24 - PR Newswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast ...
04.09.24 - PR Newswire
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire
08.08.24 - PR Newswire
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
09.07.24 - PR Newswire
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma PR Newswire
10.05.24 - PR Newswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-...
09.05.24 - PR Newswire
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
02.04.24 - PR Newswire
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 PR Newswire
14.03.24 - PR Newswire
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update PR Newswire
14.03.24 - PR Newswire
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 PR Newswire
21.02.24 - PR Newswire
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference PR Newswire
03.01.24 - PR Newswire
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program PR Newswire
12.12.23 - PR Newswire
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer PR Newswire
08.12.23 - PR Newswire
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-​Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS PR Newswire
01.12.23 - PR Newswire
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium PR Newswire
13.11.23 - PR Newswire
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update PR Newswire

Newssuche

Videos

08:20 Uhr
Technical Trading: Baumwolle Long, weil...
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »